tbuckley/cabot-search huggingface dataset:
Abstract 37: Interleukin-10 Deficiency Can Alter Contents and Further Impair Functions of Exosomes Derived From Endothelial Progenitor Cells
Authors: Yujia Yue, Venkata N Garikipati, Suresh K Verma, David Goukassian, Cindy Benedict, Raj Kishore
Journal: Circulation Research (2017)

Endothelial progenitor cell (EPC) based therapy has been shown to have an immense potential to promote cardiac neovascularization and to attenuate ischemic injury. Recent research revealed that the therapeutic performance of stem cells is largely due to paracrine effects, in which exosomes (Exo) play an essential role. However, the autologous transplantation of EPCs in patients with systemic inflammation, which is a common symptom in patients with ischemic heart diseases, yield modest results, suggesting the compromised cell function and altered Exo performance. So we hypothesized that EPCs under inflammatory stress might change Exo contents, which eventually compromises their repair ability in ischemic heart disease. Whether modulation of identified targets like specific microRNAs in Exo cargo can rescue and/or enhance their reparative properties of dysfunctional Exo is not known. We have previously shown in IL-10 KO mice (model mimicking systemic inflammation) that loss of Interleukin-10 (IL-10) impairs EPCs functions via miR-375. After cell expansion, we isolated Exo from these two groups and compared their functions in terms of cell survival, proliferation, migration and angiogenic capacity in vitro . Our studies revealed that WT-EPC-Exo treatment enhanced endothelial cells proliferation and tube formation and inhibited apoptosis; whereas IL-10 KO-Exo exhibited opposite effects, suggesting that reparative capacity of WT-EPC Exo is lost in Exo derived from IL-10-KO-EPCs. The deep sequencing and proteomic analysis between WT and IL-10KO-Exo revealed drastically altered Exosomal cargo. Importantly, IL-10KO-EPC-Exos were highly enriched in microRNAs and proteins related to pro-inflammation, cell apoptosis and anti-angiogenesis. Through modulation of specific target (here as miR-375), we partially rescued IL-10KO-EPC-Exo dysfunction. Taken together, our study revealed that Exo display impaired function under inflammatory stimulus via changing Exo contents, and the dysfunction can be rescued by modulation specific target packed in Exo.
Improving health care for the poor. Lessons from the 1980s
Authors: E. Ginzberg
Journal: JAMA (1994)

ALTHOUGH the details of the Clinton Health Security Plan have yet to be debated and acted on by the Congress, it is reasonably certain that the country is on its way to providing coverage for essential health care services to all Americans. Accordingly, it may be both timely and helpful to report the findings of a study of the changing US health care delivery system seen through the mirror of the nation's four largest metropolitan areas—New York, NY, Chicago, Ill, Houston, Tex, and Los Angeles, Calif. The study was undertaken by the Eisenhower Center staff at Columbia University, New York, in the late 1980s in collaboration with three field associates with the support of the Robert Wood Johnson Foundation.<sup>1</sup>Our primary focus was the changing structures for delivering health care services to the poor, and we believe that the findings hold lessons for the nation as it seeks to
Journal club
Authors: Sachin Ananth
Journal: Thorax (2021)

Dysbiosis of the gut microflora is associated with the development of asthma, and antibiotic use is a risk factor for dysbiosis.However, it is unclear if antibiotic stewardship in young children is associated with a reduction in asthma incidence.Patrick et al (Lancet Respir Med 2020;8:1094) performed a populationbased study of paediatric antibiotic prescribing and asthma incidence in British Columbia, Canada, between 2000 and 2014.Antibiotic use and asthma incidence were also assessed in 2644 children recruited to a longitudinal birth cohort from cities across Canada.The authors sequenced the gut microbiota of 917 of these children in their first year of life, to examine any relationships among microbiota diversity, asthma incidence and antibiotic use.Over the study period (2000)(2001)(2002)(2003)(2004)(2005)(2006)(2007)(2008)(2009)(2010)(2011)(2012)(2013)(2014), the incidence of asthma in children aged 1-4 years old decreased by 26.0%, while antibiotic prescriptions in the first year of life decreased by 61.0%.Multivariate analysis demonstrated that a 10% increase in antibiotic prescribing was associated with a 24% increase in asthma incidence (adjusted incident rate ratio 1.24, 95% CI 1.20 to 1.28).After excluding children who received antibiotics for a respiratory cause (to reduce confounding), multivariate analysis of the birth cohort showed that antibiotic use in the first year of life was associated with asthma at age 5 years (aOR 2.15, 95% CI 1.37 to 3.39).This association demonstrated a significant dose-response effect.Structural equation modelling demonstrated that gut microbiota was a significant mediator between antibiotic use in the first year of life and development of asthma by age 5 years (β=0.07).While studies of the airway microbiota are needed, these findings suggest that antibiotic stewardship in infancy may contribute to the reduction in asthma incidence at a population level.this work.
Subacute carbon monoxide poisoning. Another great imitator
Authors: T. W. Grace
Journal: JAMA (1981)

The illnesses of two patients with characteristic symptoms of subacute carbon monoxide poisoning were misdiagnosed initially. This resulted in the needless exposure of one patient and two relatives to a toxic environment. The cherry-red color of the skin commonly cited in the literature was absent in both patients. The carbon monoxide poisoning probably contributed to the myocardial infarction and pulmonary emboli seen in these patients. Vague flu-like illnesses should raise the suspicion of carbon monoxide poisoning. (<i>JAMA</i>1981;246:1698-1700)
Abstract 4629: FOXA2 controls tumor-associated inflammation in<i>KRAS</i>-mutant lung cancer
Authors: Koichi Tomoshige, Minzhe Guo, Iris Fink-Baldauf, William Stuart, Yutaka Maeda
Journal: Cancer Research (2019)

Abstract Background: Although the role of the transcription factor FOXA2 in lung cancer has been investigated using mouse and human lung cancer cell lines, to our knowledge, the role of FOXA2 in autochthonous lung tumors in GEMM (Genetically Engineered Mouse Model) has not been determined. Methods: In order to determine the role of FOXA2 in autochthonous lung tumor cells, we deleted FOXA2 in lung epithelia of Kras-mutant lung cancer model mice (Scgb1a1-Cre;[tetO]-Kras4bG12D;Foxa2flox/flox, a GEMM) and assessed survival and lung histology of the GEMM. Results: Deletion of FOXA2 in autochthonous Kras-mutant lung tumor cells significantly extended the survival of Kras-mutant lung cancer model mice (median survival from 8 weeks to 23 weeks; n&amp;gt;14 for each group). Histological analysis indicated that FOXA2 was required for the growth of lung tumor cells and the recruitment of tumor-associated macrophages. Conclusion: FOXA2 promotes primary KRAS-mutant lung tumors in part by controlling tumor-associated inflammation. Citation Format: Koichi Tomoshige, Minzhe Guo, Iris Fink-Baldauf, William Stuart, Yutaka Maeda. FOXA2 controls tumor-associated inflammation inKRAS-mutant lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4629.
Oral Contraceptives—
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Foods of the future. The new biotechnology and FDA regulation
Authors: H. I. Miller
Journal: JAMA (1993)

ALTHOUGH most of the genetically altered "foods of the future" are similar to the foods we are familiar with, the techniques of the new biotechnology are subtly changing and improving the foods we eat. The Food and Drug Administration (FDA) already has paved the way for the arrival of the new food products and processes by announcing on May 29, 1992, its policy on the oversight of new varieties of food plants.<sup>1</sup>But because of the scientific issues involved (eg, allergenicity) as well as consumers' reservations about such products and their general lack of understanding of the FDA's policy, it is important that physicians—a trusted source of health-related advice—be informed on the nuances of the subject. This article attempts to place in a scientific perspective new crop varieties obtained by conventional and new techniques and describes the FDA's approach to their oversight. <h3>The History of Genetic Engineering Applied to</h3>
Abstract 14729: Weight Loss Reduces Atrial Fibrillation Inducibility and Burden in Severe Obesity Induced by Either High-Fat Diet or Genetic Hyperphagia in Mice
Authors: Eleonora Savio-Galimberti, Prince Kannankeril, David Wasserman, Dawood Darbar
Journal: Circulation (2015)

Introduction: Atrial fibrillation (AF), the most common sustained arrhythmia worldwide, is associated with increased morbidity and mortality. Obesity is increasingly recognized as an important risk factor to develop AF and heart disease with a diet rich in fats leading to morbid obesity. Melanocortin-4 receptor (MC4R) gene is a critical regulator of energy homeostasis, and homozygous loss-of-function mutations cause hyperphagia and morbid obesity. Hypothesis: We hypothesized that obesity and its comorbidities can create a profibrillatory substrate for AF in high fat diet-induced obese (DIO) and MC4R knock-out (MC4R-KO) mice, and that this substrate can be reversed by weight loss. Methods: Transesophageal rapid pacing was performed using atrial burst pacing (cycle length: 50-15 ms, for 15 s) to determine AF inducibility (% of mice that develop AF) and AF burden (number of AF episodes and total AF duration/mouse) in lightly anesthesized normotensive mice (C57bl6 mice [LEAN], DIO, and MC4R-KO), with continuous ECG monitoring. Transthoracic echocardiography was performed to assess right (R) and left (L) atrial appendage (AA) sizes. Results: Atrial burst pacing induced AF in 91% of DIO and 100% of MC4R-KO vs. 50% of LEAN (P&lt;0.01, N=8 mice/group). Compared to LEAN, both DIO and MC4R-KO exhibited greater number of inducible AF episodes (0.7±0.2 vs. 1.8±0.2 vs. 1.8±0.1, P&lt;0.01, N=15 mice/group) with longer duration (17.9±3 vs. 196±22 vs. 244±34 s, P&lt;0.0001, N=15 mice/group; Figure). Both DIO and MC4R-KO had greater LAA volumes as compared with LEAN (5.2±0.2 vs. 6.7±0.4 vs. 4.1±0.1 μl, P&lt;0.01, N=8 mice/group). RAA volume was similar across groups. After 20% weight loss, both AF burden and LAA volumes were significantly reduced to those seen in LEAN (22±5 s, 4.5±0.1 μl, P&lt;0.001, N=8 mice/group). Conclusions: High-fat diet or genetic hyperphagia-induced obesity increases LAA volume and creates a profibrillatory substrate for AF that can be reversed with weight loss.
Wrong Affiliation and Missing Minus Sign
Journal: JAMA (1983)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Foetal Cries
Authors: W. G. Mills
Journal: BMJ (1947)

so many patients to take even elementary precautions against the spreading of infection.The other extreme is the mother who is over-anxious about infecting her child, and one has known this constant worry to have caused deterioration of the mother's general health, followed by a flare-up of the old disease.I have at present a patient who was confined shortly before her admission to sanatorium.Neighbours agreed to take the baby on the understanding that as soon as the mother completed treatment the baby was to be returned to her.On discharge the mother was still an open case.The fact that she now realizes that there is little hope of her becoming fit enough to take the child back (he is unwanted by his foster parents) is, in my opinion, largely responsible for her present rapid deterioration.Prolonged anteand post-partum institutional treatment is advocated, but how can this be carried out with the extreme staff and bed shortages now prevailing ?Lack of domestic help, added financial strain, and sleepless nights all help to undermine the patient's already devitalized system.These factors, together with many others, need careful consideration before finally condemning abortion in tuberculosis cases.The pathological lung changes are of less interest to me than these other possible catastrophes.As an employee of a service whose motto is, "The Prevention, Treatment, and Abolition of Tuberculosis," I deplore this drive for babies without full regard to the conseqqences.-Iam, etc., Lianelly, Carmarthenshire.
Multicenter phase II study of concurrent high-dose (72Gy) three-dimensional conformal radiotherapy (3D-CRT) without elective nodal irradiation with chemotherapy using cisplatin and vinorelbine for unresectable stage III non-small cell lung cancer (NSCLC).
Authors: Hidehito Horinouchi, Ikuo Sekine, Minako Sumi, Miyako Satouchi, Hiroshi Isobe, Masao Harada, Seiji Niho, Kiyoshi Mori, Tomohide Tamura
Journal: Journal of Clinical Oncology (2012)

7070 Background: The optimal dose of radiotherapy remains unclear in concurrent chemoradiotherapy for unresectable stage III NSCLC. We previously concluded that the recommended dose for further trial was 72Gy in a phase I study (Sekine et al., Int J Radiat Oncol Biol Phys. 953-959, 2012). Methods: Eligible patients (unresectable stage III NSCLC, age between 20 and 74, PS 0-1, V 20 ≤ 30%) received cisplatin (80 mg/m 2 day 1) and vinorelbine (20 mg/m 2 days 1 and 8) repeated every 4 weeks for 3-4 cycles. The 3D-CRT started at the first day of chemotherapy at a total dose of 72 Gy in 36 fractions. The primary endpoint was a 2-year survival rate and the planned sample size was 60 to reject the rate of 45% under the expectation of 65% with a power of 90% and an alpha error of 5%. Results: Thirty-one patients from 4 institutions were enrolled between May 2009 and March 2010. This trial was terminated early due to slow accrual and grade 5 pulmonary toxicities in 2 patients. There were 25 men and 6 women with a median (range) age of 59 (32-72) years. Of these, 23 had adenocarcinoma and 21 had stage IIIA disease. The median (range) V 20 value was 20 (9-30). The full planned dose of radiotherapy could be administered in 30 (97%) patients, and 26 (84%) of the patients received 3-4 cycles of chemotherapy. During the chemoradiotherapy, grade 3-4 febrile neutropenia, infection and esophagitis were noted in 5, 4 and 1 of the 31 patients, respectively. After completion of the planned chemoradiotherapy, 5 patients had grade 3 or higher radiation pneumonitis, and 2 (6%) of these patients died at 6.6 and 7.3 months after the treatment started. The overall response rate was 97% (95% confidence interval: 83.3-99.9). Twenty-four patients are alive and thirteen patients experienced recurrence (2 had loco-regional recurrences, 7 had distant recurrence and 4 had mixed recurrence pattern) at a median follow up of 16.4 months. Conclusions: Concurrent high-dose (72Gy) 3D-CRT with chemotherapy using cisplatin and vinorelbine may have a too excessive incidence of pulmonary toxicities to warrant any further evaluation.
Cardiopulmonary resuscitation
Authors: C. Köppel, B. Klapp, J. P. Sculiar, E. Markiewicz, A. Brinkmann, Ch. -F. Wolf, J. Wiebemeit, D. Rigos, F. Keck, E. G. Pfenninger, K. H. Lindner, H. Wiedeck, A. Prengel, A. Goertz, S. Rapp, F. W. Ahnefeld, C. Tormo, J. A. Cantalapiedra, N. Perales, P. Ferrer, G. Albiñana, E. Vega, C. Peréz, R. Sesma, J. García, R. Alcaide
Journal: Intensive Care Medicine (1992)
Use of Umbilical Vein for Transfusion of Newborn Babies
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TRAUMATIC RUPTURE OF THE HEART WITHOUT EXTERNAL LESION.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Drug therapy of hyperlipoproteinemia
Authors: R. I. Levy
Journal: JAMA (1976)

MANAGEMENT of hyperlipoproteinemia has been advanced considerably in recent years through new insights into lipid and lipoprotein metabolism, as well as into the mode of action of hypolipidemic drugs.<sup>1</sup>A variety of highly effective lipid levellowering drugs is now available.<sup>2</sup>Because of the heterogeneity of the hyperlipoproteinemias, no single drug is useful in all the disorders. We now know that elevated lipid levels are the result of increased production or decreased removal of specific lipoproteins. Thus, the efficacy of a specific drug is determined by its effect on production or removal of the lipoproteins present in excess in each type of hyperlipoproteinemia.<sup>3</sup> Hypolipidemic drugs can control hyperlipoproteinemia by one of two
Generalized Anhidrosis Associated with Hodgkin's Disease and Acquired Ichthyosis
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correction
Authors: Chiesi Farmaceutici, Caterina Brindicci, Tim Higenbottam, Thierry Trooster, Fabienne Dobbels, ; Glaxo, Smith Kline, Margaret Tabberer, Roberto Rabinovich, Bill Mcnee, Michael Polkey, Nick Hopkinson, Judith Garcia-Aymerich, Milo Puhan, Anja Frei, Thys Van Der Molen, Ian Jarrod, Paul Mcbride, Nadia Kamel, ; Pfizer, Katja Rudell, Frederick Wilson, ; Almirall, Nathalie Ivanoff, Karoly Kulich, Alistair Glendenning, Astrazeneca Ab, Niklas Karlsson
Journal: Thorax (2014)
From the authors
Authors: R. M. van Leeuwen, A. W. J. Bossink, S. F. T. Thijsen
Journal: European Respiratory Journal (2007)

VAN LEEUWEN et al. [1] mention that speed to rule out TB is of great importance in terms of infection-control measures.However, with the exception of immunosuppressed individuals or young children in whom immediate clinical work-up is mandatory, IGRA tests and TST take 6-8 weeks to convert after infection: no large-scale contact-tracing procedure is warranted for the first 2 months following diagnosis and treatment of the index case.